Physician profile
Lance Williamson
NPI 1114285723
$4,063.99
in general payments reported to CMS, 2019-2025
24 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $888 · 2023: $838 · 2024: $1,045 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.97 |
| Education | $221.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $822.97 | 2021-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $470.40 | 2021-2024 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals LP | $462.13 | 2021-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $370.66 | 2021-2024 | Rayaldee |
| Travere Therapeutics, INC. | $272.60 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $239.57 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $217.08 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $190.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $185.73 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $145.42 | 2021-2024 | Jynarque |
| Horizon Therapeutics Plc | $110.88 | 2021-2023 | Krystexxa |
| Amgen INC. | $96.39 | 2021-2024 | Krystexxa |
| Glaxosmithkline, LLC. | $86.09 | 2022-2024 | Jesduvroq, Benlysta |
| Aurinia Pharma U.S., INC. | $66.45 | 2022-2023 | Lupkynis |
| Akebia Therapeutics INC | $66.18 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.28 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $48.40 | 2023 | Purified Cortrophin Gel |
| Ardelyx, INC. | $39.91 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $31.75 | 2024 | |
| Scpharmaceuticals INC. | $23.79 | 2025 | |
| Kyowa Kirin, INC. | $18.47 | 2023 | |
| Shield Therapeutics INC | $15.36 | 2023 | Accrufer |
| Lilly USA, LLC | $14.81 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.